We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01655316
First Posted: August 1, 2012
Last Update Posted: November 14, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Tehran University of Medical Sciences
July 30, 2012
August 1, 2012
November 14, 2012
October 2010
August 2011   (Final data collection date for primary outcome measure)
Recurrence Control [ Time Frame: 2 hours ]
Same as current
Complete list of historical versions of study NCT01655316 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control
Not Provided

PSVT is a common rhythm disorder in emergency department which can be recurrent in some cases.

Intravenous Adenosine is the drug of choice in PSVT control in acute settings but is a very short acting agent.

Providing a complementary medication to decrease the rate of recurrence of PSVT after its initial control will be promising.

This study evaluates the role of the oral Verapamil in recurrence control of PSVT in emergency situations.

Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Paroxysmal Supraventricular Tachycardia
Drug: Verapamil
Experimental: Verapamil
40 mg Verapamil Per Oral
Intervention: Drug: Verapamil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
90
August 2011
August 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age>18 years old
  • PSVT on emergency department presentation

Exclusion Criteria:

  • Instability in hemodynamic status
  • Allergy to Verapamil
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01655316
16062
No
Not Provided
Not Provided
Tehran University of Medical Sciences
Tehran University of Medical Sciences
Not Provided
Not Provided
Tehran University of Medical Sciences
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP